Compound Intelligence / Metabolic Research

Tirzepatide LY3298176

Exploring dual-receptor agonism and the interconnected roles of GIP and GLP-1 signaling in glucose homeostasis, metabolic regulation, and energy balance.

Synthetic Peptide Dual Receptor Agonist Metabolic Research
RESEARCH USE ONLY
Independently supplied laboratory material. Not for human or veterinary use. Not an FDA-approved pharmaceutical product.
Compound Class Peptide
Receptor Targets 2 Pathways
Molecular Weight ~4,813.5 Da
Receptor Activity GIPR / GLP-1R
Scientific Overview

What Is Tirzepatide?

Tirzepatide (LY3298176) is a synthetic peptide that activates two hormone receptors involved in metabolic regulation: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor.

Classified as a dual GIP/GLP-1 receptor agonist, tirzepatide has been extensively investigated for its effects on glucose regulation, insulin signaling, appetite-related pathways, and energy homeostasis.

Its dual-receptor pharmacology provides a framework for understanding how complementary incretin signaling pathways influence metabolic physiology.

Mechanism of Action

Two Receptors. Complementary Pathways.

Tirzepatide activates GIP and GLP-1 receptors, which belong to the G protein-coupled receptor family. Both pathways participate in nutrient-responsive endocrine signaling and metabolic regulation.

01
GIPR

GIP Receptor

GIP receptor activation contributes to glucose-dependent insulin secretion and nutrient-responsive metabolic signaling. The pathway is involved in pancreatic beta-cell function and the physiological response to nutrient intake.

02
GLP-1R

GLP-1 Receptor

GLP-1 receptor activation supports glucose-dependent insulin secretion, suppression of inappropriate glucagon secretion, delayed gastric emptying, and central appetite-related signaling. These mechanisms contribute to the regulation of glucose and energy balance.

Why dual-receptor activity matters: GIP and GLP-1 signaling pathways share complementary roles in metabolic regulation. Their combined activation has been investigated to better understand interactions between insulin secretion, glucose homeostasis, and energy regulation.
Areas of Investigation

Research Applications

Tirzepatide has been investigated across several areas of metabolic and endocrine science, particularly those involving incretin receptor signaling.

⌬

Incretin Signaling

Interactions between GIP and GLP-1 receptor pathways and their downstream cellular responses.

◇

Glucose Homeostasis

Hormonal mechanisms influencing insulin secretion, glucagon regulation, and glucose metabolism.

◎

Pancreatic Beta-Cell Function

Investigation of nutrient-dependent insulin signaling and pancreatic endocrine responses.

⚡

Energy Homeostasis

Relationships between hormonal signaling, nutrient intake, and energy balance.

⬡

Receptor Pharmacology

Dual-receptor agonism, receptor selectivity, and intracellular signaling mechanisms.

✧

Metabolic Regulation

Interactions among endocrine, gastrointestinal, and central signaling pathways.

These research applications describe scientific areas of investigation. They do not establish the safety, efficacy, or clinical suitability of independently supplied research materials.
Published Research

Scientific Background

Tirzepatide was developed by Eli Lilly and Company and has undergone extensive clinical investigation involving metabolic and endocrine conditions.

Clinical research programs have examined the pharmacological effects of simultaneous GIP and GLP-1 receptor activation.

Tirzepatide is the active ingredient in FDA-approved prescription medications. Those approvals apply to specific regulated pharmaceutical products, indications, and manufacturing standards.

Published clinical findings do not establish the identity, purity, safety, or pharmaceutical equivalence of independently supplied laboratory research materials.

PEER-REVIEWED PUBLICATION

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

Frías JP, et al. New England Journal of Medicine. 2021;385:503–515.

View Scientific Publication
Compound Data

Product Specifications

General compound characteristics and listed research material information. Batch-specific analytical documentation should be reviewed when available.

Compound Name Tirzepatide
Research Identifier LY3298176
Compound Type Synthetic Peptide
Receptor Activity GIPR / GLP-1R
Molecular Formula C225H348N48O68
Molecular Weight ~4,813.5 g/mol
Physical Form Lyophilized Powder
Listed Sizes 5 mg / 10 mg / 20 mg / 30 mg
Research Category Metabolic / Endocrine
Pharmaceutical Status Active ingredient in FDA-approved prescription medications
Laboratory Practices

Storage & Laboratory Handling

Tirzepatide research material should be stored and handled according to documented supplier specifications and applicable laboratory safety procedures.

Researchers should consult available batch-specific documentation for recommended storage conditions, stability information, and handling requirements.

Appropriate protective equipment and established laboratory protocols should be used when handling research compounds.

Important / Research Use Disclaimer

For Laboratory Research Only

Tirzepatide is the active ingredient in FDA-approved prescription medications. However, independently supplied research materials are not thereby FDA-approved pharmaceutical products.

Materials supplied by Titan Helix Biosciences are designated for laboratory research and analytical investigation only. They are not represented as equivalent to approved pharmaceutical products or materials used in clinical trials.

Not for human or veterinary use. Not intended for administration, consumption, diagnosis, treatment, prevention, or cure of any disease.

Research materials should be handled only by appropriately qualified laboratory personnel in suitable research environments.